Rain Therapeutics Inc Investor Relations Material
Rain Therapeutics Inc, a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers.
Key slides for Rain Therapeutics Inc
Rubrik's 2024 IPO: What Investors Need To Know
Explore Rubrik's journey to a 2024 IPO, its innovative cybersecurity solutions, and strategic growth, highlighting its impact on the tech sector.
29 Feb 2024
Pricing Power Through Scarcity: A Case Study of Ferrari
Explore how Ferrari's scarcity and brand strength amplify its pricing power, crucial for a luxury company's success.
27 Feb 2024
Jacob Wallenberg: The Chairman of Investor AB
Get to know Jacob Wallenberg, one of the most influential businessmen in Europe and a part of the fifth generation of the Wallenberg family.
28 Feb 2024
🇺🇸 United States